Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XL 888

Next Previous
Drug Profile

XL 888

Alternative Names: EXEL-4888; Heat Shock Protein 90 Inhibitor XL888; Hsp90 Inhibitor XL888; XL888

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Emory University; Exelixis; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Gastrointestinal cancer
  • No development reported Malignant melanoma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO)
  • 02 Feb 2023 XL 888 is still in phase I trials for Malignant melanoma in the US (NCT01657591)
  • 02 Feb 2023 Exelixis completes a phase I trial for Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT01657591)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top